Vassiliki Pappa

1.4k total citations
48 papers, 736 citations indexed

About

Vassiliki Pappa is a scholar working on Hematology, Genetics and Oncology. According to data from OpenAlex, Vassiliki Pappa has authored 48 papers receiving a total of 736 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Hematology, 13 papers in Genetics and 13 papers in Oncology. Recurrent topics in Vassiliki Pappa's work include Acute Myeloid Leukemia Research (19 papers), Chronic Lymphocytic Leukemia Research (10 papers) and Lymphoma Diagnosis and Treatment (9 papers). Vassiliki Pappa is often cited by papers focused on Acute Myeloid Leukemia Research (19 papers), Chronic Lymphocytic Leukemia Research (10 papers) and Lymphoma Diagnosis and Treatment (9 papers). Vassiliki Pappa collaborates with scholars based in Greece, United States and United Kingdom. Vassiliki Pappa's co-authors include Sotirios G. Papageorgiou, Theofanis Economopoulos, S. Raptis, Panayoula C. Tsiotra, Christos K. Kontos, Andreas Scorilas, John Dervenoulas, Constantine Tsigos, Panagiota Economopoulou and Panagiotis Tsirigotis and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Vassiliki Pappa

47 papers receiving 728 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Vassiliki Pappa Greece	15	243	223	204	193	169	48	736
Oscar Muñoz United States	10	130 0.5×	160 0.7×	186 0.9×	86 0.4×	80 0.5×	19	637
Dina Attias Israel	16	205 0.8×	218 1.0×	169 0.8×	215 1.1×	205 1.2×	46	864
Isabel Granada Spain	15	190 0.8×	135 0.6×	217 1.1×	292 1.5×	463 2.7×	53	870
Barbara Buldini Italy	19	159 0.7×	196 0.9×	274 1.3×	145 0.8×	671 4.0×	56	1.2k
Sylvie François France	21	315 1.3×	433 1.9×	234 1.1×	326 1.7×	648 3.8×	67	1.3k
A. Klepfish Israel	15	85 0.3×	147 0.7×	44 0.2×	102 0.5×	105 0.6×	27	484
Dolors Costa Spain	21	280 1.2×	190 0.9×	299 1.5×	417 2.2×	400 2.4×	73	1.2k
H. Behrendt Netherlands	24	368 1.5×	259 1.2×	325 1.6×	226 1.2×	419 2.5×	74	1.5k
J. P. Jouet France	18	88 0.4×	220 1.0×	127 0.6×	229 1.2×	807 4.8×	34	1.1k
Corinne Rusterholz Switzerland	18	215 0.9×	224 1.0×	358 1.8×	83 0.4×	56 0.3×	39	1.6k

Countries citing papers authored by Vassiliki Pappa

Since Specialization

Citations

This map shows the geographic impact of Vassiliki Pappa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vassiliki Pappa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vassiliki Pappa more than expected).

Fields of papers citing papers by Vassiliki Pappa

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vassiliki Pappa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vassiliki Pappa. The network helps show where Vassiliki Pappa may publish in the future.

Co-authorship network of co-authors of Vassiliki Pappa

This figure shows the co-authorship network connecting the top 25 collaborators of Vassiliki Pappa. A scholar is included among the top collaborators of Vassiliki Pappa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vassiliki Pappa. Vassiliki Pappa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Diamantopoulos, Panagiotis, Athanasios Galanopoulos, Vassiliki Pappa, et al.. (2022). Immunogenicity of a third dose of the BNT162b2 COVID-19 vaccine in patients with CLL: effects on treatment selection. Annals of Hematology. 101(12). 2711–2717. 4 indexed citations

Papageorgiou, Sotirios G., et al.. (2021). Prognostic molecular biomarkers in diffuse large B-cell lymphoma in the rituximab era and their therapeutic implications. Therapeutic Advances in Hematology. 12. 1543931747–1543931747. 14 indexed citations

Lamprianidou, Eleftheria, Anastasiya Kazachenka, Elsa Bernard, et al.. (2021). Modulation of IL-6/STAT3 signaling axis in CD4+FOXP3− T cells represents a potential antitumor mechanism of azacitidine. Blood Advances. 5(1). 129–142. 7 indexed citations

Terpos, Evangelos, Dimitris Stellas, Margherita Rosati, et al.. (2021). SARS-CoV-2 antibody kinetics eight months from COVID-19 onset: Persistence of spike antibodies but loss of neutralizing antibodies in 24% of convalescent plasma donors. European Journal of Internal Medicine. 89. 87–96. 48 indexed citations

Stamouli, Maria, Theodoros Iliakis, Thomas Thomopoulos, et al.. (2021). Allogeneic Stem Cell Transplantation with a Novel Reduced Intensity Conditioning Regimen for the Treatment of Patients with Primary Cutaneous T-cell Lymphomas. SHILAP Revista de lepidopterología. 3(2). 72–72. 3 indexed citations

Liapis, Konstantinos, Vasileios Papadopoulos, Alexandra Kourakli, et al.. (2020). Risk factors for cardiovascular disease mortality in patients with myelodysplastic syndromes: A nationwide, registry‐based cohort study. SHILAP Revista de lepidopterología. 1(1). 255–261. 2 indexed citations

Diamantopoulos, Panagiotis, Argiris Symeonidis, Ιoannis Kotsianidis, et al.. (2019). Bone Marrow Ribonucleotide Reductase mRNA Levels and Methylation Status As a Prognostic Factor in Patients with Myelodysplastic Syndrome Treated with 5-Azacytidine. Blood. 134(Supplement_1). 1721–1721. 1 indexed citations

Papageorgiou, Sotirios G., Diamantina Vasilatou, Christos K. Kontos, et al.. (2018). The prognostic value of monosomal karyotype (MK) in higher‐risk patients with myelodysplastic syndromes treated with 5‐Azacitidine: A retrospective analysis of the Hellenic (Greek) Myelodysplastic syndromes Study Group. American Journal of Hematology. 93(7). 895–901. 9 indexed citations

Papageorgiou, Sotirios G., Christos K. Kontos, Argiris Symeonidis, et al.. (2017). The Prognostic Value of Monosomal Karyotype (MK) in High-Risk Patients with Myelodysplastic Syndromes Treated with 5-Azacitidine. Blood. 130. 4252–4252. 1 indexed citations

10.

Tsirigotis, Panagiotis, et al.. (2017). Natural Killer Cell Cytotoxicity Is a Predictor of Outcome for Patients with High Risk Myelodysplastic Syndrome and Oligoblastic Acute Myeloid Leukemia Treated with Azacytidine. Blood. 130. 2976–2976. 1 indexed citations

11.

Hatzigeorgiadis, Antonis, Vassiliki Pappa, Kalliopi Georgakouli, et al.. (2016). Self-regulation strategies may enhance the acute effect of exercise on smoking delay. Addictive Behaviors. 57. 35–37. 12 indexed citations

12.

Lamprianidou, Eleftheria, Theodoros P. Vassilakopoulos, Sotirios G. Papageorgiou, et al.. (2015). The Stat3/5 Signaling Biosignature in Hematopoietic Stem/Progenitor Cells Predicts Response and Outcome in Myelodysplastic Syndrome Patients Treated with Azacitidine. Clinical Cancer Research. 22(8). 1958–1968. 16 indexed citations

13.

Adamopoulos, Panagiotis G., Christos K. Kontos, Sotirios G. Papageorgiou, Vassiliki Pappa, & Andreas Scorilas. (2015). KLKB1 mRNA overexpression: A novel molecular biomarker for the diagnosis of chronic lymphocytic leukemia. Clinical Biochemistry. 48(13-14). 849–854. 21 indexed citations

14.

Papageorgiou, Sotirios G., Amanda Psyrri, Vassiliki Pappa, et al.. (2010). Hypoxia-inducible factors in mantle cell lymphoma: implication for an activated mTORC1→HIF-1α pathway. Annals of Hematology. 90(3). 315–322. 21 indexed citations

15.

Psyrri, Amanda, Sotirios G. Papageorgiou, Andreas Scorilas, et al.. (2009). Phosphatidylinositol 3′-Kinase Catalytic Subunit α Gene Amplification Contributes to the Pathogenesis of Mantle Cell Lymphoma. Clinical Cancer Research. 15(18). 5724–5732. 86 indexed citations

16.

Economopoulou, Christina, Vassiliki Pappa, Sotirios G. Papageorgiou, et al.. (2009). Cell cycle and apoptosis regulatory gene expression in the bone marrow of patients with de novo myelodysplastic syndromes (MDS). Annals of Hematology. 89(4). 349–358. 19 indexed citations

17.

Papageorgiou, Sotirios G., Vassiliki Pappa, Christina Economopoulou, et al.. (2007). Hypermethylation of the p15^INK4B gene promoter in B‐chronic lymphocytic leukemia. American Journal of Hematology. 82(9). 824–825. 12 indexed citations

18.

Tsirigotis, Panagiotis, Vassiliki Pappa, Stefanos Labropoulos, et al.. (2006). Mutational and methylation analysis of the cyclin‐dependent kinase 4 inhibitor (p16^INK4A) gene in chronic lymphocytic leukemia. European Journal Of Haematology. 76(3). 230–236. 14 indexed citations

19.

Kopterides, Petros, et al.. (2005). Cytarabine-induced lung injury: case report. Anti-Cancer Drugs. 16(7). 743–745. 7 indexed citations

20.

Papageorgiou, Sotirios G., Vassiliki Pappa, E. Papageorgiou, et al.. (2005). Absence of p16 and p27 gene rearrangements and mutations in de novo myelodysplastic syndromes. European Journal Of Haematology. 75(3). 193–198. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact